Analysts Set C4 Therapeutics, Inc. (NASDAQ:CCCC) PT at $10.13

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) have received an average recommendation of “Hold” from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $10.13.

A number of research analysts have commented on CCCC shares. Stifel Nicolaus upped their target price on shares of C4 Therapeutics from $13.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. Wells Fargo & Company upped their price objective on shares of C4 Therapeutics from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Thursday, May 9th.

Institutional Investors Weigh In On C4 Therapeutics

Large investors have recently added to or reduced their stakes in the business. Barclays PLC boosted its position in C4 Therapeutics by 30.7% in the 3rd quarter. Barclays PLC now owns 43,614 shares of the company’s stock valued at $81,000 after buying an additional 10,246 shares during the period. Citigroup Inc. grew its stake in C4 Therapeutics by 214.6% during the 3rd quarter. Citigroup Inc. now owns 57,894 shares of the company’s stock worth $108,000 after purchasing an additional 39,492 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in C4 Therapeutics during the 4th quarter worth about $49,000. Raymond James & Associates raised its position in C4 Therapeutics by 10.5% in the 4th quarter. Raymond James & Associates now owns 100,984 shares of the company’s stock valued at $571,000 after purchasing an additional 9,604 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new position in shares of C4 Therapeutics in the 4th quarter valued at about $39,000. 78.81% of the stock is owned by hedge funds and other institutional investors.

C4 Therapeutics Stock Performance

CCCC stock opened at $4.52 on Friday. C4 Therapeutics has a one year low of $1.06 and a one year high of $11.88. The firm has a market cap of $311.00 million, a PE ratio of -1.91 and a beta of 3.07. The firm’s 50 day moving average price is $5.38 and its 200-day moving average price is $6.65.

C4 Therapeutics (NASDAQ:CCCC) last posted its earnings results on Wednesday, May 8th. The company reported ($0.41) EPS for the quarter, meeting analysts’ consensus estimates of ($0.41). The company had revenue of $3.04 million for the quarter, compared to the consensus estimate of $10.93 million. C4 Therapeutics had a negative return on equity of 52.85% and a negative net margin of 629.24%. Equities research analysts predict that C4 Therapeutics will post -1.56 EPS for the current fiscal year.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.